Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...
The world’s first-ever lung cancer vaccine trial has just begun, with experts hopeful about the “groundbreaking” phase 1 ...